Moliris, Inc. Announces Focus on the Development of Treatment for Antibiotic Resistant Staph Infections.

FORT WORTH, Texas -- Moliris Inc. (OTCBB:MOLR) announced today that the Company will focus its technology resources initially on the development of its leading Product Candidate bacteriophage for the treatment of antibiotic-resistant Staph infections.

Resistant Staph infections are most commonly caused by Staphylococcus aureus in the form known as Methicillin-Resistant Staph Aureus (MRSA). The Moliris bacteriophages are being developed as alternatives to conventional antibiotics. MRSA is well recognized as a major cause of 'Hospital-Acquired' (Nosocomial) infections worldwide. Researchers have recently identified 'Community-Acquired' MRSA as a distinct variation of Nosocomial MRSA. The standard treatment for infections caused by MRSA is Vancomycin, although the adequacy of this drug is being questioned because of its inconsistent activity in infections caused by Vancomycin-Intermediate-Resistant Staph Aureus (VISA).

Three antibiotics are approved currently for use as alternatives to Vancomycin in infections caused by MRSA (quinupristin-dalfopristin, linezolid, and daptomycin); bacterial resistance has now emerged to all three of these drugs. The emergence of Vancomycin-Resistant Staph-Aureus (VRSA) represents an even greater threat in what appears to be a continuing stream of resistant forms of Staph. Moliris intends to initiate scale-up manufacturing of its bacteriophage Product Candidate for the treatment of resistant forms of Staphylococcus aureus during 2005.

About Moliris, Inc.:

Moliris is engaged in the development, manufacturing and regulatory approval of new products for the treatment of antibiotic-resistant bacterial infections. Moliris Corp. acquired Mycobis' core technology in the form of specific bacterial viruses, known as bacteriophages, and the associated bacterial host producer strains, plus all of the associated skill-in-the-art and know how. The terms of the asset acquisition agreement include the development and marketing rights of the resulting antimicrobial products. Moliris will bring forward the bacteriophage products as a new class of biopharmaceuticals. Moliris will manufacture the bacteriophage products and will seek regulatory approval by the US Food and Drug Administration for their use as therapeutic agents for the treatment of antibiotic-resistant Staph infections. Hospital-acquired and community-acquired Staph infections account for as many as 100,000 deaths per year in the US alone, plus an even greater number of deaths in the rest of the world, most especially in developing countries. Antibiotic-resistant strains of Staphylococcus aureus, such as MRSA (Methicillin-Resistant Staphylococcus aureus) and other resistant forms of Staph, cost the US health care system more than $4.5 billion and more than 8 million added hospital days annually. The medical crisis of multi-resistant infections continues to grow.

"Safe Harbor Statement" Under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements that involve risks and uncertainties. The statements in this Release are forward-looking statements that are made pursuant to safe harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results, events and performance could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from results expressed or implied by forward-looking statements. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making investment decisions.